The initial descriptions of an increase in PSMA expression in prostate cancer was associated with higher tumor grade with the presence of metastases (Bostwick et al., 1998; Sweat et al., 1998; Chang et al., 2001) suggesting that PSMA is a highly plausible target for PSMA-positive prostate cancer therapy and since has been adopted as a biomarker for diagnosis and imaging (Barve et al., 2014). The gene discussed is FOLH1; the disease is prostate cancer.